EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer’s Disease

Manoj Govindarajulu, Priyanka D Pinky iD, Jenna Bloemer iD, Nila Ghanei, Vishnu Suppiramaniam iD, Rajesh Amin iD

PPAR Research · 21.10.2018 · 2018 · 1-20

DOI: 10.1155/2018/2010675 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PPAR Research, erschienen am 21.10.2018. Verfasst von Manoj Govindarajulu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute for Health Research.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a chronic neurodegenerative disease characterized by abnormal protein accumulation, synaptic dysfunction, and cognitive impairment. The continuous increase in the incidence of AD with the aged population and mortality rate indicates the urgent need for establishing novel molecular targets for therapeutic potential. Peroxisome proliferator-activated receptor gamma (PPAR γ ) agonists such as rosiglitazone and pioglitazone reduce amyloid and tau pathologies, inhibit neuroinflammation, and improve memory impairments in several rodent models and in humans with mild-to-moderate AD. However, these agonists display poor blood brain barrier permeability resulting in inadequate bioavailability in the brain and thus requiring high dosing with chronic time frames. Furthermore, these dosing levels are associated with several adverse effects including increased incidence of weight gain, liver abnormalities, and heart failure. Therefore, there is a need for identifying novel compounds which target PPAR γ more selectively in the brain and could provide therapeutic benefits without a high incidence of adverse effects. This review focuses on how PPAR γ agonists influence various pathologies in AD with emphasis on development of novel selective PPAR γ modulators.

Autor:innen und Institutionen

  • Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
  • Center for Neuroscience, Auburn University, Auburn, AL, USA.

ORCID-Profile: Priyanka D Pinky, Jenna Bloemer, Vishnu Suppiramaniam, Rajesh Amin

Förderung

  • NIA NIH HHS
  • National Institute for Health Research

Zitieren

APA

Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V., & Amin, R. (2018). Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer’s Disease. PPAR Research, 2018, 1-20. https://doi.org/10.1155/2018/2010675

Vancouver

Govindarajulu M, Pinky PD, Bloemer J, Ghanei N, Suppiramaniam V, Amin R. Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer’s Disease. PPAR Research. 2018;2018:1-20. doi:10.1155/2018/2010675

BibTeX
@article{Govindarajulu2018,
  author = {Govindarajulu, Manoj and Pinky, Priyanka D and Bloemer, Jenna and Ghanei, Nila and Suppiramaniam, Vishnu and Amin, Rajesh},
  title = {Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer’s Disease},
  journal = {PPAR Research},
  year = {2018},
  volume = {2018},
  pages = {1--20},
  doi = {10.1155/2018/2010675}
}
Kostenlos starten →